Metformin is a biguanide compound, supplied here as a 500mg extended-release (ER) tablet. It is studied for its role in AMPK activation and the glucose-regulation and metabolic pathways associated with this compound.

This extended-release formulation is used in controlled laboratory workflows and in-vitro systems examining AMPK signaling, glucose metabolism, and insulin-sensitivity mechanisms. It is applied in structured research models characterizing compound activity and downstream pathway interactions.

Metformin supports analytical studies and cell-based models involving AMPK activation, glucose- and insulin-related pathways, mitochondrial activity, and broader metabolic efficiency. It is relevant for pathway characterization and assay development focused on metabolic and longevity mechanisms within controlled study frameworks.

Metformin ER is suited for researchers and investigators studying AMPK signaling, glucose regulation, and metabolic-efficiency mechanisms within controlled study frameworks.